tirzepatide dose increase Mounjaro (tirzepatide) - Diabetes & Wieght Loss When Should You Go Up

A standalone comorbid indication is defensible on mechanistic grounds and would allow a tighter label with stronger effect size claims

Semaglutide treated diabetes, got approved for obesity, and spawned an entire category

From fatty liver to fibrosis: a tale of second hit. World J Gastroenterol

But, if you have access to both, we would recommend the following: If your health would benefit from the higher percentage weight loss (15-20%) of Zepbound / tirzepatide, and you have not had a cardiac event, Zepbound offers modestly more weight loss with fewer side effects

What the Current Evidence Says About Long-Term Outcomes Phase 2 data show substantial short-term weight loss with retatrutide, but long-term evidence beyond 48 weeks is limited